Skip to main content

Table 2 Grade ≥ 2 and grade ≥ 3 acute HT(excluding and including lymphopenia), leukopenia, neutropenia, anemia, thrombocytopenia and lymphopenia for all patients

From: Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study

 

Grade ≥ 2

Grade ≥ 3

 

BMS (n = 121)

Control (n = 121)

P

BMS (n = 121)

Control (n = 121)

P

HT(excluding lymphopenia)

88(72.70%)

110(90.90%)

P < 0.001*

20(16.50%)

79(65.30%)

P < 0.001*

Leukopenia

80(66.10%)

103(85.10%)

0.001*

16(13.20%)

66(54.50%)

P < 0.001*

Neutropenia

45(37.20%)

80(66.10%)

P < 0.001*

13(10.70%)

53(43.80%)

P < 0.001*

Anemia

21(17.40%)

37(30.60%)

0.016*

5(4.10%)

11(9.10%)

0.121

Thrombocytopenia

25(20.70%)

40(33.10%)

0.030*

5(4.10%)

8(6.6%)

0.392

Lymphopenia

119(98.30%)

120(99.20%)

1.000

109(90.10%)

107(88.40%)

0.678

HT(including lymphopenia)

121(100.00%)

120(99.20%)

1.000

110(90.90%)

116(95.90%)

0.121

  1. Abbreviation HT, hematologic toxicity; BMS, bone marrow sparing; ns, no significance. * P < 0.05 was considered significant